Patients continued their existing metformin regimen without modification, and the combination worked as expected
Nephrologists defined their ideal patient as someone with diabetic kidney disease exhibiting persistently elevated urinary albumin-to-creatinine ratio (ACR) or decline in eGFR with proper reninangiotensinaldosterone system (RAAS) blockade, starting with SGLT2is first and subsequently adding GLP1-RAs
( D ) Different representation of data presented in Figure 3C
Semaglutide is sold under three brand names, each with slightly different dosing profiles: Ozempic injectable, once-weekly, approved for type 2 diabetes and cardiovascular risk reduction Wegovy injectable, once-weekly, higher dose (up to 2.4 mg), approved for weight management Rybelsus oral tablet, taken daily, approved for type 2 diabetes All three share the same active ingredient and similar side-effect profiles, though Wegovy at higher doses tends to cause more frequent GI symptoms